Evonik has officially unveiled a pioneering initiative to develop a new biodegradable polymer platform, signaling a significant shift in how the pharmaceutical industry approaches the environmental impact of drug manufacturing. By integrating sustainability directly into the development of its renowned EUDRAGIT functional excipients, the company aims to modernize oral drug delivery systems without sacrificing the high standards of efficacy and regulatory compliance required for patient safety.
For decades, EUDRAGIT polymethacrylate-based polymers have served as the gold standard for oral drug delivery, enabling critical functions such as controlled-release coatings and solubility enhancement for poorly soluble drug substances. While these materials have been lauded for their clinical performance, Evonik’s latest development addresses an increasingly urgent demand: the need for products that do not leave a lasting environmental footprint.
The new polymers are engineered to maintain the technical superiority of current industry-standard excipients while introducing a biodegradable end-of-life profile. According to Evonik, these materials have demonstrated strong performance under rigorous testing, meeting international biodegradability standards—specifically OECD 301 F and OECD 301 B protocols—where they have achieved degradation levels exceeding 60%.
“Sustainability is becoming a design criterion in pharmaceutical development, alongside quality, efficacy and safety,” said Thilo Krapfl, head of Oral Drug Delivery Solutions at Evonik Health Care. “With the next generation of EUDRAGIT, we are moving from measuring sustainability to actively engineering it.”
This advancement is particularly notable for its compatibility with existing pharmaceutical infrastructure. Evonik has designed the platform to work seamlessly with current manufacturing technologies, such as hot-melt extrusion and spray drying. This allows formulators to transition to more sustainable materials without the need for costly retrofitting of production facilities or significant overhauls to existing drug development workflows.
The move comes as environmental responsibility rises to the forefront of the global pharmaceutical agenda. As regulatory agencies and consumer advocates push for greener supply chains, the ability to incorporate sustainability at the molecular level of drug design represents a competitive advantage. Currently, non-commercial, laboratory-scale quantities of these biodegradable polymers are available for select partners interested in joint development projects.
This development reflects a broader, industry-wide effort to reconcile the strict requirements of pharmaceutical production with the growing necessity of ecological stewardship. By proving that high-performance excipients can be environmentally conscious, Evonik is setting a new benchmark for the sector, suggesting that the future of drug delivery lies in the balance of therapeutic precision and environmental sustainability. As the project moves into its collaborative testing phase, the industry will be watching closely to see how these next-generation materials redefine the parameters of future pharmaceutical formulations.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
